Abbott Laboratories, a healthcare giant based in North Chicago, Illinois, is valued at $230.9 billion, known for brands like Ensure and FreeStyle Libre. It operates in 160 countries, focusing on innovation in diagnostics, diabetes care, and nutrition. Despite a recent dip, ABT has outperformed the iShares U.S. Medical Devices ETF in the long term.

ABT released its Q2 results on Jul. 17, reporting revenue growth of 7.4% to $11.1 billion, beating estimates. Its adjusted EPS of $1.26 increased 10.5% year-over-year. However, despite the strong performance, ABT shares dropped by 8.5% post-earnings release. Analysts are optimistic, giving ABT a “Strong Buy” rating with a mean price target of $144.22.

Read more at Yahoo Finance: How Is Abbott Laboratories’ Stock Performance Compared to Other Medical Devices Stocks?